189 related articles for article (PubMed ID: 31570326)
1. Nivolumab-associated bullous pemphigoid reactions involving multiple epitopes.
Aoki Y; Miyagawa F; Miyashita K; Nishimura Y; Hashimoto T; Asada H
Eur J Dermatol; 2019 Oct; 29(5):552-554. PubMed ID: 31570326
[No Abstract] [Full Text] [Related]
2. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
[No Abstract] [Full Text] [Related]
3. Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient.
Chersi F; Conforti C; Zalaudek I; Bazzacco G; Zelin E; di Meo N
Melanoma Res; 2023 Jun; 33(3):262-263. PubMed ID: 37114722
[No Abstract] [Full Text] [Related]
4. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid.
Ridpath AV; Rzepka PV; Shearer SM; Scrape SR; Olencki TE; Kaffenberger BH
Int J Dermatol; 2018 Nov; 57(11):1372-1374. PubMed ID: 29624655
[No Abstract] [Full Text] [Related]
5. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
Grimaux X; Delva R; Jadaud E; Croue A
Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
[No Abstract] [Full Text] [Related]
6. Dyshidrosiform pemphigoid due to nivolumab therapy.
Hayashi W; Yamada K; Kumagai K; Kono M
Eur J Dermatol; 2021 Jun; 31(3):411-412. PubMed ID: 34309527
[No Abstract] [Full Text] [Related]
7. Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab.
Grän F; Goebeler M; Gesierich A
Eur J Dermatol; 2019 Aug; 29(4):448-449. PubMed ID: 31625927
[No Abstract] [Full Text] [Related]
8. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
[No Abstract] [Full Text] [Related]
9. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma.
Korman AM; Tyler KH; Kaffenberger BH
Int J Dermatol; 2017 Apr; 56(4):e75-e77. PubMed ID: 28102540
[No Abstract] [Full Text] [Related]
10. A case of bullous pemphigoid in a malignant melanoma patient following an increased Th2/Th1 ratio in peripheral blood cells after nivolumab treatment.
Fukuchi K; Shimauchi T; Fujiyama T; Ito T; Honda T
Eur J Dermatol; 2023 Oct; 33(5):550-551. PubMed ID: 38297931
[No Abstract] [Full Text] [Related]
11. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.
Kwon CW; Land AS; Smoller BR; Scott G; Beck LA; Mercurio MG
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e349-e350. PubMed ID: 28129461
[No Abstract] [Full Text] [Related]
12. Detection of IgG antibodies to BP180 NC16a and C-terminal domains and LAD-1 in nivolumab-associated bullous pemphigoid.
Matsui Y; Makino T; Ishii N; Hashimoto T; Shimizu T
Eur J Dermatol; 2019 Oct; 29(5):554-555. PubMed ID: 31570332
[No Abstract] [Full Text] [Related]
13. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.
Sowerby L; Dewan AK; Granter S; Gandhi L; LeBoeuf NR
JAMA Dermatol; 2017 Jun; 153(6):603-605. PubMed ID: 28355425
[No Abstract] [Full Text] [Related]
14. Bullous pemphigoid exacerbated by nivolumab and temporally rescued with therapeutic plasma exchange.
Waki Y; Nobeyama Y; Chujo S; Asahina A
J Dermatol; 2024 May; 51(5):e149-e150. PubMed ID: 38010735
[No Abstract] [Full Text] [Related]
15. Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
Anastasopoulou A; Papaxoinis G; Diamantopoulos P; Christofidou E; Benopoulou O; Stratigos A; Gogas H
J Immunother; 2018 Apr; 41(3):164-167. PubMed ID: 29309291
[TBL] [Abstract][Full Text] [Related]
16. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
17. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.
Amber KT; Valdebran M; Lu Y; De Feraudy S; Linden KG
J Dtsch Dermatol Ges; 2018 Feb; 16(2):196-198. PubMed ID: 29389067
[No Abstract] [Full Text] [Related]
18. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
19. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
[No Abstract] [Full Text] [Related]
20. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma.
Pach J; Olamiju B; Weiss S; Damsky W; Leventhal J
JAMA Dermatol; 2021 Apr; 157(4):468-469. PubMed ID: 33688919
[No Abstract] [Full Text] [Related]
[Next] [New Search]